Interestingly, CD39+ Treg cells are able to efficiently suppress IL-17 production by Th17 cells, contrary to their CD39− counterpart, thus their reduction in MS patients may participate to the ineffective control of Th17-driven inflammation in this disease (183). This evidence concerns the gene ENTPD1 and myeloid sarcoma.